Industry Experts

Christoph Rader joined Aethon Therapeutics (New York, NY) as Chief Technology Officer in 2023 following an academic career as professor and principal investigator at The Scripps Research Institute in Jupiter, FL (2012-2023; acquired by the University of Florida in 2022), the National Cancer Institute (NCI) of the National Institutes of Health (NIH) in Bethesda, MD (2003-2012), and The Scripps Research Institute in La Jolla, CA (1999-2003). His laboratories pursued both antibody drug and target discovery for cancer therapy, with a focus on antibody display, engineering, and conjugation technologies. Aethon Therapeutics discovers and develops T-cell engagers to target synthetic and natural pMHC derived from modified and amplified oncoproteins.